Daniel Electronic.

Nessel, M.D., John F. Paolini, M.D., Ph.D., Scott D. Berkowitz, M.D., Keith A.A. Fox, M.B., Ch.B., Robert M. Califf, M.D., and the ROCKET AF Steering Committee for the ROCKET AF Investigators: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Atrial fibrillation is associated with an increase in the risk of ischemic stroke by a factor of four to five1 and accounts for up to 15 percent of strokes in persons of most ages and 30 percent in persons over the age of 80 years.2 The use of vitamin K antagonists is highly effective for stroke prevention in individuals with nonvalvular atrial fibrillation and is preferred for individuals at increased risk.3-5 However, medication and food interactions necessitate frequent coagulation monitoring and dose adjustments, requirements which make it difficult for many patients to use such medicines in clinical practice.6-8 Rivaroxaban is a direct factor Xa inhibitor that might provide more predictable and consistent anticoagulation than warfarin.55 females will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy. Historically, when provided the very best regimen tested to date even, these patients had a median survival of around six a few months with just five % surviving one 12 months. ‘This design greatly increases the clinical development of ADXS11-001 in a number of ways,’ said Dr. John Rothman, EVP of Functions and Science.